Pegol-Sihematide

DRUG3 trials

Sponsors

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Conditions

AnemiaChronic Kidney DiseasesChronic Renal FailureDialysisNon-Dialysis-Dependent Chronic Kidney Disease

Phase 2

Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis

Jiangsu Hansoh Pharmaceutical Co., Ltd.Anemia, Chronic Renal Failure, Dialysis

Start: 2015-10-31End: 2016-08-31Target: 60Updated: 2015-10-26

Phase 3

Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With Chronic Kidney Disease on Dialysis

CompletedNCT03902691

Jiangsu Hansoh Pharmaceutical Co., Ltd.Chronic Kidney Diseases

Start: 2019-05-15End: 2022-05-30Updated: 2023-03-09

Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With NDD-CKD

Jiangsu Hansoh Pharmaceutical Co., Ltd.Non-Dialysis-Dependent Chronic Kidney Disease

Start: 2019-06-20End: 2022-12-31Updated: 2022-09-01

Related Papers

Randomized Trial of Pegmolesatide for the Treatment of Anemia in Patients With Nondialysis CKD

Kidney International Reports2024-12-064 citations

Pegmolesatide for the treatment of anemia in patients undergoing dialysis: a randomized clinical trial.

2023-10-288 citations